CPI-637 as a Potential Bifunctional Latency-Reversing Agent That Targets Both the BRD4 and TIP60 Proteins
Authors:
Open Access
- 19 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11
Abstract
The failure of highly active antiretroviral therapy (HAART) has been largely responsible for the existence of latent human immunodeficiency virus type 1 (HIV-1) reservoirs. The “shock and kill” strategy was confirmed to reactivate HIV-1 latent reservoirs by latency-reversing agents (LRAs) for accelerated HIV-1 clearance. However, a single LRA might be insufficient to induce HIV-1 reactivation from latency due to the complexity of the multiple signaling regulatory pathways that establish the HIV-1 latent reservoir. Therefore, combinations of LRAs or dual-mechanism LRAs are urgently needed to purge the latent reservoirs. We demonstrate here for the first time that a dual-target inhibitor with a specific suppressive effect on both BRD4 and TIP60, CPI-637, could reactivate latent HIV-1 in vitro by permitting Tat to bind positive transcription elongation factor b (P-TEFb) and assembling Tat-super-elongation complex (SEC) formation. In addition, CPI-637-mediated TIP60 downregulation further stimulated BRD4 dissociation from the HIV-1 long terminal repeat (LTR) promoter, allowing Tat to more effectively bind P-TEFb compared to BRD4 inhibition alone. Much more importantly, CPI-637 exerted a potent synergistic effect but alleviated global T cell activation and blocked viral spread to uninfected bystander CD4+ T cells with minimal cytotoxicity. Our results indicate that CPI-637 opens up the prospect of novel dual-target inhibitors for antagonizing HIV-1 latency and deserves further investigation for development as a promising LRA with a “shock and kill” strategy.Keywords
This publication has 46 references indexed in Scilit:
- HIV-1 transcription and latency: an updateRetrovirology, 2013
- The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivationNucleic Acids Research, 2012
- Bromodomain and Extra-terminal (BET) Bromodomain Inhibition Activate Transcription via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear RibonucleoproteinJournal of Biological Chemistry, 2012
- Reactivation of Latent HIV-1 by Inhibition of BRD4Cell Reports, 2012
- Endotoxin-induced cytokine and chemokine expression in the HIV-1 transgenic ratJournal of Neuroinflammation, 2012
- Regulation of chromatin by histone modificationsCell Research, 2011
- UHRF1 recruits the histone acetyltransferase Tip60 and controls its expression and activityBiochemical and Biophysical Research Communications, 2009
- Physiological evidence for interaction between the HIV‐1 co‐receptor CXCR4 and the cannabinoid system in the brainBritish Journal of Pharmacology, 2009
- A mathematical approach to study combined effects of toxicants in vitro: Evaluation of the Bliss independence criterion and the Loewe additivity modelToxicology in Vitro, 2007
- Control of the Histone-Acetyltransferase Activity of Tip60 by the HIV-1 Transactivator Protein, TatBiochemistry, 1999